Inogen, Inc. — Q2 2016 Form 10-Q
Reporting period: Three and six months ended June 30, 2016. Financial statements are unaudited; dollar amounts below are in millions unless stated otherwise.
Business context
Inogen develops, manufactures and markets portable oxygen concentrators and related products. It earns revenue from product sales and rentals, including direct-to-consumer sales and rentals and business-to-business sales. The company reported one business segment and sold products in 44 countries outside the United States.
Financial results and liquidity
| Metric | Q2 2016 | Q2 2015 | First half 2016 | First half 2015 |
|---|---|---|---|---|
| Total revenue | $54.6 | $44.0 | $97.6 | $77.8 |
| Sales revenue | $45.6 | $32.4 | $78.4 | $55.4 |
| Rental revenue | $9.0 | $11.6 | $19.2 | $22.3 |
| Gross profit | $26.2 | $20.8 | $47.5 | $36.8 |
| Gross margin | 48.0% | 47.3% | 48.7% | 47.4% |
| Operating income | $8.0 | $5.3 | $11.3 | $7.9 |
| Net income | $5.1 | $3.5 | $7.5 | $5.0 |
| Diluted earnings per share | $0.25 | $0.17 | $0.36 | $0.24 |
| Adjusted EBITDA (non-GAAP) | $13.6 | $9.6 | $21.7 | $15.9 |
Q2 sales revenue rose 40.7%, driven mainly by higher system volumes; rental revenue fell 22.8%. The company sold about 25,100 systems in Q2 versus 16,400 a year earlier, and about 42,100 in the first half versus 27,400. Sales gross margin improved to 49.4% in Q2 and 49.5% for the first half, while rental gross margin declined to 41.0% and 45.2%, respectively. The overall margin gain reflected stronger sales margins and a larger sales contribution.
For the first half, operating cash flow was $16.8, versus $13.8 in 2015. Investing activities used $0.7, versus $22.0, largely reflecting investment maturities and purchases; capital expenditure was $4.2. Financing activities provided $2.3. Cash and cash equivalents were $84.5 at June 30, with $13.6 of short-term investments; net working capital was $114.6. The company had no borrowings on its $15.0 revolving facility and $0.159 of current patent-purchase debt. It reported compliance with its credit covenants, with covenant EBITDA of $38.2 against a $12.5 minimum and tangible net worth of $147.3 against a $90.0 minimum.
Material changes and outlook
- Management attributed sales growth to stronger domestic and international business-to-business demand and increased direct-to-consumer sales and marketing. Q2 sales also benefited from seasonal spring and summer travel demand.
- Medicare reimbursement reductions and increased rental-revenue adjustments weighed on rentals. Management expected 2016 rental revenue to decline approximately 25% from 2015, with additional pressure from private-payor rate reductions and fewer net patient additions as the company prioritized sales.
- Management estimated that competitive-bidding and related rate changes would reduce 2016 total revenue by approximately 3.5%–4.0%. Round two re-compete rates took effect July 1, 2016; management said it expected to retain access to over 90% of the Medicare market.
- The Inogen One G4 launched in May 2016. Management expected manufacturing capacity to ramp through Q3, domestic business-to-business launch in Q3, and international business-to-business launch in Q4 2016 or early 2017, subject to regulatory and reimbursement approvals. An upgraded G3 battery was expected by year-end 2016.
- Management expected research and development, sales and marketing, and general and administrative spending to increase in absolute dollars. It stated that available liquidity and expected cash generation should meet operating and investing needs for at least 12 months; this is not a quantified revenue or earnings forecast.
Risks, contingencies and unusual items
- Reimbursement and collections: Medicare represented 14.1% of first-half total revenue, and 71.8% of rental revenue came from Medicare service reimbursement programs. Competitive bidding, further reimbursement cuts, claim audits, prior authorization, capped rentals and private-payor rate pressure could affect revenue, margins and cash collection.
- Receivables and working capital: Net accounts receivable increased to $27.8 from $19.9 at year-end 2015; inventory rose to $12.5 from $8.6. Operating cash flow included significant working-capital use, including a $18.4 accounts-receivable cash outflow. Allowances for doubtful accounts, rental adjustments and sales returns totaled $8.6.
- Legal matters: Inogen settled its patent dispute with Inova Labs for $1.25; it recorded a $1.0 gain in Q2 and received payment July 26, 2016. A further $0.25 gain contingency was not recorded. The company accrued approximately $0.98 for a mediated California wage-and-hour settlement, which had preliminary court approval after quarter-end. The SDGIP patent, trade-secret and contract suit remained contested; damages sought were unspecified.
- Operations and market exposure: The company relies on a limited number of suppliers for some components, has $37.3 of outstanding purchase orders, and faces manufacturing ramp and product-acceptance risks. Foreign exchange exposure is partly hedged; international sales, reimbursement rules and currency movements remain risks.
- Other items: Stock-based compensation rose to $3.5 in the first half from $1.3. The company reported effective disclosure controls and no material change in internal control over financial reporting during Q2. It had previously remediated a revenue-documentation control material weakness.
Key facts for investors to verify
- Whether the sharp growth in system sales continues and converts into sustained revenue and cash flow.
- Actual rental revenue, rental margins and receivable collections after the July 2016 reimbursement changes.
- Progress on G4 production capacity, channel launches and required regulatory or reimbursement approvals.
- Final court approval and payment of the wage-and-hour settlement, and developments in the SDGIP litigation.
- Compliance with credit-facility covenants and management’s liquidity assumptions, particularly if operating performance or collections weaken.